QUIZ is a second-generation type I FLT3i that can achieve significant marrow remissions in R/R FLT3-mutant AML [116, 137–139], though survival advantage was minimal compared to salvage chemotherapy in the phase 3 QuANTUM-R study [138]. Here, FLT3 is linked to acute myeloid leukemia.